COMBINATION OF CHEMOTHERAPY AND HORMONE-THERAPY IN ADVANCED BREAST-CANCER

被引:0
|
作者
MERKLE, E [1 ]
BAR, I [1 ]
HENKE, A [1 ]
BUHNER, M [1 ]
WILDT, L [1 ]
MARTUS, P [1 ]
LANG, N [1 ]
机构
[1] UNIV ERLANGEN NURNBERG,INST MED STAT & DOKUMENTAT,W-8520 ERLANGEN,GERMANY
关键词
ADVANCED BREAST CANCER; COMBINED THERAPY; DECAPEPTYL(R); RESPONSE RATE;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In a prospective study at the Department of Obstetrics and Gynaecology, University of Erlangen, patients with advanced breast carcinoma were treated with a combination of chemotherapy and hormone therapy. Patients received one injection of Decapeptyl(R) in a 28 days interval. At day 12 and 13 of the treatment cycle 40 mug of ethinylestradiol were applicated followed by intravenous chemotherapy with 500 mg/m2 fluorouracil, 10 mg/m2 mitoxantrone and 500 mg/m2 cyclophosphamide took place on day 14. 39 patients were integrated in this study. All of these patients were evaluable regarding the side-effects and 36 patients concerning the response rate. In case of response after 6 cycles the interval between the chemotherapy was prolonged to 6 weeks and the Decapeptyl(R) injections remained in a 4 weeks interval. 15 patients received this combined therapy as a first-line therapy, 24 patients as a second-line therapy or third-line therapy. 2 patients had a complete remission, 14 patients had a partial remission. The objective response rate (CR+PR) was therefore 44 %. In 8 patients the response was classified as no change, consequently the total response rate (CR + PR + NC) was 67 %. 12 patients showed a progression (33 %), 2 patients with several previous treatments suffered an early progress. 3 patients did not finish the therapy. The median response duration was 9 months and the median follow up time until now is 13 months; 24 patients died. Therapy related side-effects were tolerable. As the most frequent side-effect bone marrow suppression were observed. Subjective, for the patients most inconvenient side-effects like nausea, vometing, and alopecia seldomly appeared. The combination of chemotherapy and hormone therapy achieved with a good toleration response rates, which are compatible to international standards of chemotherapy. The exspectations to achieve a better remission rate by a combination of chemotherapy and hormone therapy rather than chemotherapy alone were not fulfilled in this studie.
引用
收藏
页码:220 / 223
页数:4
相关论文
共 50 条
  • [11] HORMONE-THERAPY IN METASTASIZED BREAST-CANCER
    MIGNOT, L
    SEMAINE DES HOPITAUX, 1985, 61 (35-3): : 2541 - 2543
  • [12] COMBINED ADJUVANT HORMONE-THERAPY AND CHEMOTHERAPY IN FEMALE BREAST-CANCER PATIENTS
    ZIELINSKI, C
    KUBISTA, E
    AIGINGER, P
    SALZER, H
    SEVELDA, P
    LANGER, M
    STAFFEN, A
    SPONA, J
    KUZMITS, R
    WIENER KLINISCHE WOCHENSCHRIFT, 1987, 99 (03) : 96 - 96
  • [13] COMBINATION HORMONE-THERAPY FOR METASTATIC BREAST-CANCER - AN ECOG STUDY OF MEGESTROL AND AMINOGLUTETHIMIDE
    HORTON, J
    KNUIMAN, M
    KELLER, AM
    VOGEL, H
    GALE, KE
    HAHN, RG
    ROSENBLUTH, RJ
    TORMEY, DC
    CANCER, 1987, 60 (09) : 2137 - 2140
  • [14] NEW ASPECTS IN HORMONE-THERAPY OF METASTATIC BREAST-CANCER
    HOFFKEN, K
    MILLER, AA
    MILLER, B
    BECHER, R
    SCHMIDT, CG
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1985, 110 (47) : 1799 - 1802
  • [15] EXPERIMENTAL AND CLINICAL ASPECTS OF HORMONE-THERAPY IN BREAST-CANCER
    MAASS, H
    JONAT, W
    ARCHIV FUR GESCHWULSTFORSCHUNG, 1981, 51 (07): : 623 - 629
  • [16] PREDNISONE AS HORMONE-THERAPY OF BREAST-CANCER IN THE METASTATIC PHASE
    MOUSSEAU, M
    SWIERCZ, P
    SCHAERER, R
    BULLETIN DU CANCER, 1985, 72 (04) : 347 - 347
  • [17] BREAST-CANCER, THERAPEUTIC CASTRATION, AND REPLACEMENT HORMONE-THERAPY
    SCHIFF, I
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1984, 251 (18): : 2426 - 2426
  • [18] MITOMYCIN-C IN METASTATIC BREAST-CANCER RESISTANT TO HORMONE-THERAPY AND CONVENTIONAL CHEMOTHERAPY
    DELENA, M
    JIRILLO, A
    BRAMBILLA, C
    VILLA, S
    TUMORI, 1980, 66 (04) : 481 - 487
  • [19] MITOMYCIN-C IN PATIENTS WITH METASTATIC BREAST-CANCER REFRACTORY TO HORMONE-THERAPY AND CHEMOTHERAPY
    LOPEZ, M
    PAPALDO, P
    DILAURO, L
    BARDUAGNI, M
    PERNO, CF
    BARDUAGNI, A
    ONCOLOGY, 1983, 40 (04) : 244 - 247
  • [20] PSYCHOLOGICAL PROFILES OF BREAST-CANCER PATIENTS ON ADJUVANT HORMONE-THERAPY
    CUMMING, CE
    HANDMAN, M
    LEES, A
    KRAUSHER, RJ
    CUMMING, DC
    NEUROPSYCHOPHARMACOLOGY, 1993, 9 (02) : S88 - S88